New AI tools predict diabetic kidney disease from retinal images, flag hemodialysis patients at hospitalization risk, and advance lupus nephritis care. Findings were presented at ARVO 2026 and published in NEJM Catalyst, The Lancet, and the International Journal of Molecular Sciences.
A 2026 review outlines the shift in solid organ transplantation from broad immunosuppression to Treg-based active tolerance. It covers polyclonal Tregs, CAR-Tregs and CRISPR-edited off-the-shelf products.
New therapies including CAR-T, bispecific antibodies and dual-antibody immunotherapy are reshaping multiple myeloma care. Advances in genomic testing may also improve risk assessment and treatment decisions.
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.
More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
A CNIC study demonstrates that remote ischemic conditioning can protect the heart during anthracycline chemotherapy without compromising antitumor efficacy, while researchers explore additional methods to manage chemotherapy side effects.
The FDA has approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration BTK inhibitor-based regimen for previously untreated adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Orca-T, an investigational T-cell therapy under FDA priority review, is being studied to reduce graft-versus-host disease in patients undergoing allogeneic stem cell transplant for acute leukemias and high-risk blood disorders, with a decision expected in April 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07770334 |
Procalcitonin as a Prognostic Predictor in Patients With Acute Infectious Disease Hospitalized in the Internal Medicine Department. |
NOT_YET_RECRUITING | |
| NCT07756554 |
Clinical Assessment and Treatment in the Nursing Home as an Alternative to Hospital Admission |
RECRUITING | NA |
| NCT07720856 |
Surgical Recovery Support Pillow for Spine Surgeries |
RECRUITING | NA |
| NCT07706608 |
DRONE-WOUND Study: Severe Infection After Drone-Related Combat Trauma |
NOT_YET_RECRUITING | |
| NCT07684300 |
Molecular Microbiology- Guided Antimicrobial Stewardship Versus Standard Stewardship in Hospitalized Patients |
RECRUITING | NA |
| NCT07673484 |
Tattooing and Piercing Among Medical Students |
COMPLETED | |
| NCT07665476 |
Naproxen Versus Placebo as Adjunct Treatment of Cellulitis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07645079 |
Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes Care |
NOT_YET_RECRUITING | NA |
| NCT07603128 |
Multicenter Validation of a Risk Prediction Model for MDRGNB Infection |
RECRUITING | |
| NCT07575009 |
Continuous Antibiotic Infusion In Children |
RECRUITING | PHASE3 |
